MeiraGTx Announces Data from Phase 1/2 Clinical Trial of Gene Therapy for Patients with X-linked Retinitis Pigmentosa
MeiraGTx today announced topline data from the Phase 1/2 clinical trial MGT009 (NCT03252847) of botaretigenic sparoparvovec (formerly called AAV-RPGR), an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with disease-causing variants in the RPGR gene. Treatment with botaretigen sparoparvovec was found to be generally safe and well tolerated, …